HLA新等位基因B*5827核苷酸序列的分析

目的 确认人类白细胞抗原(human leukocyte antigen,HLA)新等位基因B*5827并分析其核苷酸序列.方法 用聚合酶链反应-序列特异性寡核苷酸探针对1份HLA分型反应异常的血样进行基因分型,并用基因克隆测序技术正反向测定DNA序列.结果 测序结果显示HLA-B位点有1个与已知HLA等位基因序列均不同的新等位基因,该等位基因与HLA-B*5820序列同源性最高.但在第3外显子存在8个碱基的差异,分别为nt 290(G＞C)、nt 346(T＞A)、nt 390(A＞C)、nt 404(G＞C)、nt 413(C＞G)、nt 471(A＞G)、nt 486(A＞G)和nt 487(C＞A).碱基的不同导致了氨基酸不同nt 97(ser＞arg)、nt115(phe＞tyr)、nt 130(ser＞arg)、nt 157(thr＞ala)和nt 162(thr＞glu),其中nt 404和nt 413是同义突变.结论 该等位基因为HLA新等位基因,基因序列已提交至GenBank数据库,提交号为GU071234,于2010年1月被世界卫生组织HLA因子命名委员会正式命名为HLA-B*5827.

Abstract：

Objective To investigate the molecular basis for a novel human leukocyte antigen(HLA)allele B * 5827. Methods DNA from the proband was analyzed by polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO) typing. The amplified product was sequenced bidirectionally. Results Abnormal HLA-B locus was observed and its nucleotide sequence was different from the known HLA-B allele sequences, with highest homology to HLA-B * 5820 allele. It differs from HLA-B * 5820 by 8 nucleotide substitutions in exon 3, i. e. , nt 290 (G＞C), nt 346 (T＞A), nt 390 (A＞C), nt 404 (G＞C),nt 413 (C＞G), nt 471 (A＞G), nt 486 (A＞G) and nt 487 (C＞A), resulting in an amino acid change from ser＞arg at nt 97, phe＞tyr at nt 115, ser＞arg at nt 130, thr＞ala at nt 157 and thr＞glu at nt 162.Nucleotide differences of nt 404(G＞C) and nt 413(C＞G) did not change amino acid. Conclusion The sequences of the novel allele have been submitted to GenBank (access No. GU071234). A novel HLA class Ⅰ allele B * 5827 has been officially assigned by the WHO HLA Nomenclature Committee in Jan 2010.     

人类白细胞抗原新等位基因HLA-A*3020的鉴定及确认

目的 鉴定及确认1名中国人的人类白细胞抗原(human leukocyte antigen,HLA)新等位基因.方法 应用聚合酶链式反应-序列特异性寡核苷酸探针(polymerase chain reaction-sequence specific oligonucleotide probes,PCR-SSOP)方法基因分型、PCR产物测序和基因克隆DNA测序方法,通过软件分析该基因序列及与最相近HLA等位基因序列的差异.结果 PCR-SSOP基因分型结果显示该样品HLA-A谱型为与已知HLA-A等位基因谱型不一致的新谱型;测序结果显示该样品HLA-A位点第2外显子序列与所有已知HLA-A等位基因序列不一致.软件分析表明该基因序列与序列最相近的等位基因A*300101,在所检测的第1～3外显子中的差异只是在第2外显子区域产生了nt 294 C→A一个碱基替代,并导致相应的密码子98由GAC(D)→GAA(E).结论 该基因为HLA新等位基因,被世界卫生组织HLA因子专用术语命名委员会正式命名为HLA-A*3020.     

新等位基因HLA-B*40:96的确认及家系遗传

目的 鉴定一个中国汉族人群中发现的人类白细胞抗原(human leukocyte antigen,HLA)新等位基因,调查该基因的家系遗传情况.方法 应用Luminex DNA杂交流式分型技术进行HLA分型,发现1例HLA-B位点反应格局异常,采用DNA测序分型技术进行新等位基因鉴定并对该基因的先证者进行家系调查.结果 DNA序列确定为一个新HLA-B等位基因序列,与同源性最高的HLA-B* 40:06:01相比,在第2外显子有7个碱基不同,分别是302位G→A、309位G→C、311位A→C、313位C→G、314位T→C、317位G→T、319位G→C,并导致相应密码子编码的氨基酸发生了改变,密码子101位由丝氨酸(Ser)→天冬氨酸(Asn)、104位由天冬氨酸(Asn)→苏氨酸(Thr)、105位由亮氨酸(Leu)→丙氨酸(Ala)、106位由精氨酸(Arg)→亮氨酸(Leu)、107位由甘氨酸(Gly)→精氨酸(Arg).家系分析表明该新基因来自先证者父亲.结论 鉴定了一个HLA-B新等位基因,2009年2月被世界卫生组织HLA因子命名委员会正式命名为HLA-B* 40:96.     

沈阳汉族群体HLAⅠ类基因座PCR-序列特异性寡核苷酸探针分型研究

目的检测和分析沈阳汉族HLA-A、-B、-Cw位点等位基因的多态性。方法采用聚合酶链反应．寡核苷酸探针杂交分型方法对108名沈阳籍健康献血员进行HLA-A、-B、-Cw等位基因分型。结果检出等位基因HLA-A位点21个，B位点43个，Cw位点23个；所有位点的等位基因频率分布符合Hardy—Weinberg平衡。结论从基因水平分析了HLA Ⅰ类基因的群体分布特征，提供了沈阳汉族群体HLA Ⅰ类基因座更准确的基因频率。     

新等位基因HLA-DRB1*12:02:10的序列分析及确认

背景:人类白细胞抗原(human leukocyte antigen,HLA)个体遗传学差异的本质是在编码其抗原产物的基因水平上,各种诱导因素下所产生的新等位基因,在人群中的频率分布、抗原的血型血清学检测和生物学功能等均有待进一步研究.目的:HLA新等位基因HLA-DRB1*12:02:10的确认及序列分析.方法:采用...     

云南汉族2型糖尿病与HLA-DQA1基因的关联研究

目的　探讨云南汉族 2型糖尿病及 2型糖尿病肾病与 HL A- DQA1基因的关联性。方法　采用聚合酶链反应 -序列特异性引物技术对云南汉族 10 8例 2型糖尿病患者及 5 6名同地区同民族健康对照人群进行 DQA1基因分型。结果　云南汉族 2型糖尿病患者与正常对照组比较 ,DQA1* 0 30 1( RR=3.0 92 ,P<0 .0 1) ,DQA1* 0 5 0 1( RR=3.2 5 7,P<0 .0 5 )等位基因频率明显增高 ,DQA1* 0 4 0 1( RR=0 .371,P<0 .0 1)等位基因频率显著下降。糖尿病合并肾病组与正常对照组及不合并肾病的 2型糖尿病组比较 ,糖尿病合并肾病患者 HL A- DQA1* 0 30 2等位基因频率显著升高 ( RR=3.35 6 ,P<0 .0 1) ,各期糖尿病肾病比较中 DQA1* 0 30 2频率差异无显著性 ( P>0 .0 5 )。结论　 HL A- DQA1* 0 30 1,DQA1* 0 5 0 1是云南汉族 2型糖尿病的易感基因 ,HL A- DQA1* 0 4 0 1是云南汉族 2型糖尿病的抵抗基因 ;HL A- DQA1*0 30 2是 2型糖尿病合并肾病的易感基因     

序列分析及确认HLA新等位基因B*55:46

背景：近几年来,随着中华骨髓库的建立和人类白细胞抗原分型技术的不断发展和提高,中国人类白细胞抗原新等位基因不断被发现。 目的：探索中国人的人类白细胞抗原新等位基因。 方法：应用PCR-序列特异性寡核苷酸探针基因分型技术,对1名27岁男性汉族造血干细胞志愿捐献者进行HLA基因分型,并应用基于测序的方法分析该基因序列及与最相近等位基因序列的差异。 结果与结论：PCR-序列特异性寡核苷酸探针结果显示该样本HLA-B基因座反应格局出现异常提示;基因测序结果表明其B基因座第3外显子序列与所有已知HLA-B等位基因序列均不一致,在所检测的第2、3外显子中,与序列最相近的等位基因B*55:02:01的差异只是在第3外显子发生了nt 412 A→G一个核苷酸替代,导致第138位密码子由AAC→GAC,相应的编码的天冬酰胺改变为天冬氨酸。将其序列提交国际基因数据库及IMGT/HLA 数据库,证实该HLA等位基因为国际上首次发现,被世界卫生组织织人类白细胞抗原因子命名委员会正式命名为HLA-B*55:46 (HM989018)。     

人类白细胞抗原新等位基因B*07:110的序列分析及确认

背景：近几年来,随着中华骨髓库的建立和人类白细胞抗原分型技术的不断发展和提高,中国人类白细胞抗原新等位基因不断被发现。 目的：采用序列分析确认1例中国人的人类白细胞抗原新等位基因。 方法：应用聚合酶链式反应-序列特异性寡核苷酸探针基因分型技术进行样本的人类白细胞抗原基因分型,并应用基于测序的方法分析该基因序列及与最相近等位基因序列的差异。 结果与结论：聚合酶链式反应-序列特异性寡核苷酸探针结果显示,该样本人类白细胞抗原B基因座反应格局出现异常;基因测序结果表明,其B基因座第2外显子序列与所有已知人类白细胞抗原B等位基因序列均不一致,在所检测的第2、3外显子中,与序列同源性最高的等位基因B*07:01:02的差异是在第2外显子发生了nt 226和nt 228两个A->G核苷酸取代,导致第76位密码子由ATA->GTG,相应的导致氨基酸由异亮氨酸(I)改变为缬氨酸(V)。将其序列提交国际基因数据库(GenBank)及IMGT/HLA数据库,证实该新人类白细胞抗原等位基因为国际上首次发现,被世界卫生组织织人类白细胞抗原因子命名委员会正式命名为人类白细胞抗原B*07:110 (HM989017)。中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程全文链接：     

应用完整外显子2/3序列解决HLA-DRB1座位基因分型的歧义结果

背景：人类白细胞抗原基因测序分型中,当等位基因的差异碱基位于测序范围之外或不同等位基因对的杂合序列相同时,无法得到清晰的结果。 目的：通过完整外显子2/3序列的测定,解决常规HLA-DRB1基因分型中的高比例歧义结果。 方法：初次分型采用常规的测序方法检测320份样本的HLA-DRB1外显子2第一高变区以外的序列,测序反应设置codon86。后期采用一次性扩增外显子2/3,测序反应针对外显子2设置组特异性引物：DRB1*04/07/09为一组,其它基因家族为一组,设置conden86,对初次分型后为歧义结果的样本重新分型。 结果与结论：初次分型有180份样本为歧义结果,占总样本数的56.25 %。其中A类为差异碱基位于测序范围之外,共114例;B类为等位基因对的杂合序列相同,共17例;C类为两种情况同时存在,有49例。3种类别的歧义等位基因数分别为119个、34个、98个,占等位基因总数的33.06%、9.44 %、27.22%。完整外显子2/3序列的测定使歧义结果比例从56.25%下降到14.37%,其中A类103例、B类8例、C类23例样本的等位基因得到确认。此次研究中发现了一个新等位基因,与跟它最相近的等位基因DRB1*110101相比,其外显子3的第381位碱基G>T,导致第98位氨基酸AAG(赖氨酸 Lys)>AAT(天冬酰氨 Asn)。序列已提交Genbank,编号HM807583,2010-08被世界卫生组织HLA因子命名委员会命名为HLA-DRB1*1197(编号HWS10010999)。提示,完整外显子2/3序列的测定能大幅降低歧义分型结果的比例。     

Hallervorden-Spatz综合征 PANK2基因的突变

目的探讨泛酸激酶2(pantothenate kinase 2,PANK2)基因突变与中国人Hallervorden-Spatz综合征(Hallervorden-Spatz syndrome,HSS)的关系.方法应用聚合酶链反应、DNA直接测序、PCR产物限制性内切酶酶切和聚合酶链反应-单链构象多态性等技术检测5例HSS患者、3名家系成员及51名正常人 PANK2基因的碱基序列.结果检测出 PANK2基因一个新的复合杂合突变位于第3外显子的A803G和第5外显子的T1172A;同时检测出3个单核苷酸多态, 位于5'-UTR区的-38 t>a,第1内含子区的IVS1+42 c>a和第1外显子区的G77C,其中-38 t>a,IVS1+42 c>a为首次报道.结论中国人HSS患者存在 PANK2基因突变.     

Identification of a novel HLA-B allele, HLA-B*3713, in a Chinese individual

A novel human leukocyte antigen (HLA) class I allele, HLA-B*3713, has been identified in a Chinese individual. The HLA-B*3713 allele differs from the closest matching allele B*370101 by one nucleotide substitutions in exon 3 at nt 527(T-->A), resulting in an amino acid change from Val (GTG) to Glu (GAG) at codon 152.     

Identification of a novel allele HLA-DRB1*0478 by sequence-based typing in a Chinese individual

A novel allele HLA-DRB1*0478 is described. This variant has one nucleotide substitution in exon 2. This mutations result in an amino acid substitution at condon 70 (CAG → CGG) from Gln to Arg.     

Identification of a novel HLA-DRB1*12 allele, DRB1*1218, in Chinese population

Here, we report the identification of a novel human leukocyte antigen-DRB1*12 variant, DRB1*1218 allele, in a Chinese Han individual. The novel DRB1*12 variant allele differed from the closest allele DRB1*120201 by nucleotide 262 G>C (codon 59 GAG>CAG) missense mutation in exon 2, which resulted in an amino acid substitution of Glu>Gln.     

Full length sequence of a novel HLA-B*3818 allele differs from HLA-B*380201 allele in exon 4 and intron 5

The full length sequence of HLA-B*3818 differs from HLA-B*380201 at nt 660 in exon 4 (C→A) and genomic position 2133 in intron 5 (A→C).     

Identification of a novel HLA-B allele, HLA-B*3580, with possible implication in transplantation and CTL response

A new human leukocyte antigen (HLA)-B allele, named B*3580, with an amino acid substitution at residue 156, has been identified during the sequence-based typing of a patient waiting for a hematopoietic cell transplantation.     

A novel HLA-DRB1 allele, DRB1*112802, was identified in a Chinese individual

We report here a novel human leukocyte antigen-DRB1 allele, DRB1*112802, which was identified from a Chinese individual during sequence-based typing. The new allele is identical to DRB1*112801 except for one nucleotide change at nucleotide 189 (A → G ), codon 34 Q (CAA) → Q (CAG), no coding change.     

The distributions of HLA‐A,HLA‐B,HLA‐C,HLA‐DRB1 and HLA‐DQB1 allele and haplotype at high‐resolution level in Zhejiang Han population of China

The distributions of HLA allele and haplotype are variable in different ethnic populations and the data for some populations have been published. However, the data on HLA‐C and HLA‐DQB1 loci and the haplotype of HLA‐A, HLA‐B, HLA‐C, HLA‐DRB1 and HLA‐DQB1 loci at a high‐resolution level are limited in Zhejiang Han population, China. In this study, the frequencies of the HLA‐A, HLA‐B, HLA‐C, HLA‐DRB1 and HLA‐DQB1 loci and haplotypes were analysed among 3,548 volunteers from the Zhejiang Han population using polymerase chain reaction sequencing‐based typing method. Totals of 51 HLA‐A, 97 HLA‐B, 45 HLA‐C, 53 HLA‐DRB1 and 27 HLA‐DQB1 alleles were observed. The top three frequent alleles of HLA‐A, HLA‐B, HLA‐C, HLA‐DRB1 and HLA‐DQB1 loci were A*11:01 (23.83%), A*24:02 (17.16%), A*02:01 (11.36%); B*40:01 (14.08%), B*46:01 (12.20%), B*58:01 (8.50%); C*07:02 (18.25%), C*01:02:01G (18.15%), C*03:04 (9.88%); DRB1*09:01 (17.52%), DRB1*12:02 (10.57%), DRB1*15:01 (9.70%); DQB1*03:01 (22.63%), DQB1*03:03 (18.26%) and DQB1*06:01 (10.88%), respectively. A total of 141 HLA‐A‐C‐B‐DRB1‐DQB1 haplotypes with a frequency of ≥0.1% were found and the haplotypes with frequency greater than 3% were A*02:07‐C*01:02:01G‐B*46:01‐DRB1*09:01‐DQB1*03:03 (4.20%), A*33:03‐C*03:02‐B*58:01‐DRB1*03:01‐DQB1*02:01 (4.15%), A*30:01‐C*06:02‐B*13:02‐DRB1*07:01‐DQB1*02:02 (3.20%). The likelihood ratios test for the linkage disequilibrium of two loci haplotypes was revealed that the majority of the pairwise associations were statistically significant. The data presented in this study will be useful for searching unrelated HLA‐matched donor, planning donor registry and for anthropology studies in China.     

Characterization of a new HLA-B allele, HLA-B*5312, and re-evaluation of the published sequences of the untranslated regions of HLA-B*35 and HLA-B*53

We report a novel human leukocyte antigen (HLA)-B allele, HLA-B*5312. Compared with HLA-B*530101, there is one silent substitution at nucleotide 438 and two non-synonymous substitutions at nucleotides 431 and 440, causing a change of the amino acid sequence (Asn-->Ser at codon 77 and Ile-->Thr at codon 80, respectively) within the Bw4 epitope. In contrast to the published sequences (IMGT/HLA Database, version 2.16.0, January 2007), we found that HLA-B*530101 had a C instead of a T at nucleotide -221, whereas HLA-B*350101 had a C instead of an A at nucleotide 2992. According to our sequencing results, HLA-B*5312 resembles HLA-B*350101 regarding its sequence of the untranslated regions. HLA-B*5312 may have been the result of a double crossing over event during which HLA-B*350101 adopted a Bw4 motif.     

HLA-B*1832, a novel B allele was found through high-resolution HLA typing of a Spanish blood donor

In this paper, we describe the novel human leukocyte antigen (HLA)-B*1832 allele that we found in a female Spanish volunteer blood donor for clinical investigation during her high-resolution HLA typing. The HLA-B typing is B*1801 , 1832 , and the DNA sequence is homozygous with the exception characterized by a nucleotide exchange 'C' to 'A' at position 505, which, in consequence, replaced arginine at codon 169 (CGC) by serine in the new allele B*1832.